Gal-3 shapes antitumor-specific immune responses by suppressing activated antigen-committed CD8 T cells via LAG-3 expression in the tumor microenvironment and inhibiting expansion of plasmacytoid dendritic cells [35]. Here, CD8A is linked to neoplasm.